Government Grants
Business Grants
Home Owner Programs
Federal Programs
About Us
NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics (R61/R33 Clinical Trial Required)
The objective of this funding opportunity is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children.
In addition to supporting clinical trial start-up and implementation activities,
this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial.
All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial.
The proposed trial can be single or multisite.
This FOA will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.
In addition to supporting clinical trial start-up and implementation activities,
this FOA will provide support for final stage preclinical activities needed for the implementation of the proposed trial.
All the activities proposed in the R61 phase must be directly related to the therapeutic/diagnostic in preparation for the clinical trial.
The proposed trial can be single or multisite.
This FOA will utilize a bi-phasic, milestone-driven mechanism of award where the first phase can be used to finalize required pre-trial activities such as stability, shipping studies, and site training.
Related Programs
Department of Health and Human Services
National Center on Sleep Disorders Research
Department of Health and Human ServicesCardiovascular Diseases Research
Department of Health and Human ServicesDepartment of Health and Human Services
Blood Diseases and Resources Research
Department of Health and Human Services
Agency: Department of Health and Human Services
Office: National Institutes of Health
Estimated Funding: $2,400,000
Office: National Institutes of Health
Estimated Funding: $2,400,000
Who's Eligible
Relevant Nonprofit Program Categories
Obtain Full Opportunity Text:
http://grants.nih.gov/grants/guide/pa-files/PAR-21-119.html
Additional Information of Eligibility:
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U. S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U. S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Full Opportunity Web Address:
http://grants.nih.gov/grants/guide/pa-files/PAR-21-119.html
Contact:
Agency Email Description:
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Agency Email:
Date Posted:
2021-01-15
Application Due Date:
Archive Date:
2024-02-12
Social Entrepreneurship
Spotlight
Building a Million Dollar Company Where Everyone Counts
Ganesh Natarajan is the Founder and Chairman of 5FWorld, a new platform for funding and developing start-ups, social enterprises and the skills eco-system in India. In the past two decades, he has built two of India’s high-growth software services companies – Aptech and Zensar – almost from scratch to global success.
Learn How to Identify and Avoid Grant Scams
